OTC Markets EXMKT • USD
Calithera Biosciences, Inc. (CALA)
At close: June 5 at 1:05 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -4.8 | -3.6 | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | 9.75M | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 12/31/2021 | 3/31/2022 | 6/30/2022 | 9/30/2022 |
|---|---|---|---|---|
| EPS Est. | -4.8 | -3.7 | -2.65 | -1.93 |
| EPS Actual | -4.8 | -3.6 | -1.59 | -2.01 |
| Difference | 0 | 0.1 | 1.06 | -0.08 |
| Surprise % | 0.00% | 2.70% | 40.00% | -4.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | -1.49 | -0.52 | -8.62 | -1.35 |
| 30 Days Ago | -1.49 | -0.52 | -8.62 | -1.35 |
| 60 Days Ago | -1.49 | -0.52 | -8.62 | -1.35 |
| 90 Days Ago | -1.49 | -0.52 | -8.62 | -1.35 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CALA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 9.10% |
| Next Qtr. | -- | -- | -- | 11.50% |
| Current Year | -- | -- | -- | 5.70% |
| Next Year | -- | -- | -- | 12.60% |
| Next 5 Years (per annum) | 75.00% | -- | -- | 11.34% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Downgrade | Ladenburg Thalmann: Buy to Neutral | 11/15/2022 |
| Downgrade | SVB Leerink: Outperform to Market Perform | 11/15/2022 |
| Upgrade | HC Wainwright & Co.: Neutral to Buy | 8/29/2022 |
| Maintains | SVB Leerink: Outperform | 8/16/2022 |
Related Tickers
SYRS Syros Pharmaceuticals, Inc.
5.15
-2.83%
APLMW Apollomics, Inc.
0.0139
-30.50%
SLDB Solid Biosciences Inc.
8.06
+4.40%
SCPS Scopus BioPharma Inc.
0.0001
0.00%
CRIS Curis, Inc.
8.84
-8.49%
ARTL Artelo Biosciences, Inc.
1.3982
+0.59%
TBPH Theravance Biopharma, Inc.
8.77
-1.24%
ONPH Oncology Pharma Inc.
0.0001
+9,900.00%
SLRX Salarius Pharmaceuticals, Inc.
0.4110
-6.59%
KZIA Kazia Therapeutics Limited
0.2495
-1.73%